OM1 Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 119

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $85M

  • Investors
  • 10

OM1 General Information

Description

Developer of an outcome management platform designed to provide measurement, comparison and prediction of treatment outcomes. The company's platform gathers, synthesizes, enriches and leverages clinical data to give AI-driven insights and predictions that can improve clinical, financial and operational management, enabling healthcare organizations to analyze and use outcomes data in a clinically meaningful and precise way.

Contact Information

Website
www.om1.com
Formerly Known As
Better Outcomes
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 31 Street James Avenue
  • Suite Number 1010
  • Boston, MA 02116
  • United States
+1 (888)
Primary Industry
Outcome Management (Healthcare)
Corporate Office
  • 31 Street James Avenue
  • Suite Number 1010
  • Boston, MA 02116
  • United States
+1 (888)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OM1 Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series D) 16-Jul-2021 $85M Completed Generating Revenue
5. Later Stage VC (Series C) 18-Dec-2019 Completed Generating Revenue
4. Early Stage VC (Series B) 22-May-2018 Completed Generating Revenue
3. Early Stage VC (Series A1) 06-Apr-2017 Completed Generating Revenue
2. Early Stage VC (Series A) 25-Sep-2015 $4M $5.25M Completed Startup
1. Seed Round 01-Jan-2015 $1.25M $1.25M Completed Startup
To view OM1’s complete valuation and funding history, request access »

OM1 Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B
Series A-1
Series A 6,762,500 $0.000100 $0.13 $0.59 $0.59 1x $0.59 7.04%
Seed 3,125,000 $0.000100 $0.4 $0.4 1x $0.4 3.25%
To view OM1’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

OM1 Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an outcome management platform designed to provide measurement, comparison and prediction of treatment outc
Outcome Management (Healthcare)
Boston, MA
119 As of 2025

Richardson, TX
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OM1 Competitors (17)

One of OM1’s 17 competitors is MedeAnalytics, a Private Equity-Backed company based in Richardson, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
MedeAnalytics Private Equity-Backed Richardson, TX
Innovaccer Venture Capital-Backed San Francisco, CA
FIGmd Private Equity-Backed Rockford, IL
NantHealth Formerly VC-backed Lewisville, TX
Clinical Ink Private Equity-Backed Winston-Salem, NC
You’re viewing 5 of 17 competitors. Get the full list »

OM1 Patents

OM1 Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11862346-B1 Identification of patient sub-cohorts and corresponding quantitative definitions of subtypes as a classification system for medical conditions Active 22-Dec-2018
US-12224072-B2 Identification of patient sub-cohorts and corresponding quantitative definitions of subtypes as a classification system for medical conditions Active 22-Dec-2018
US-20240096500-A1 Identification of patient sub-cohorts and corresponding quantitative definitions of subtypes as a classification system for medical conditions Inactive 22-Dec-2018
US-20240153647-A1 Identification of patient sub-cohorts and corresponding quantitative definitions of subtypes as a classification system for medical conditions Active 22-Dec-2018
US-20250191782-A1 Identification of patient sub-cohorts and corresponding quantitative definitions of subtypes as a classification system for medical conditions Pending 22-Dec-2018 G16H50/70
To view OM1’s complete patent history, request access »

OM1 Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OM1 Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
7wire Ventures Venture Capital Minority
Breyer Capital Venture Capital Minority
D1 Capital Partners Hedge Fund Minority
Kaiser Permanente Corporation Minority
Koa Labs Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

OM1 FAQs

  • When was OM1 founded?

    OM1 was founded in 2015.

  • Where is OM1 headquartered?

    OM1 is headquartered in Boston, MA.

  • What is the size of OM1?

    OM1 has 119 total employees.

  • What industry is OM1 in?

    OM1’s primary industry is Outcome Management (Healthcare).

  • Is OM1 a private or public company?

    OM1 is a Private company.

  • What is the current valuation of OM1?

    The current valuation of OM1 is .

  • What is OM1’s current revenue?

    The current revenue for OM1 is .

  • How much funding has OM1 raised over time?

    OM1 has raised $176M.

  • Who are OM1’s investors?

    7wire Ventures, Breyer Capital, D1 Capital Partners, Kaiser Permanente, and Koa Labs are 5 of 10 investors who have invested in OM1.

  • Who are OM1’s competitors?

    MedeAnalytics, Innovaccer, FIGmd, NantHealth, and Clinical Ink are some of the 17 competitors of OM1.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process